|
HCC |Abstract Library |
 |
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
Abstract Details |
 |
|
|
|
|
|
|
|
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database |
|
|
|
|
|
Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21.
Alessandro Vitale # 1, Gianluca Svegliati-Baroni # 2 3, Alessio Ortolani 4, Monica Cucco 5 6, Giulio V Dalla Riva 7, Edoardo G Giannini 8, Fabio Piscaglia 9, Gianludovico Rapaccini 10, Mariella Di Marco 11, Eugenio Caturelli 12, Marco Zoli 13, Rodolfo Sacco 14, Giuseppe Cabibbo 15, Fabio Marra 16, Andrea Mega 17, Filomena Morisco 18, Antonio Gasbarrini 19, Francesco Giuseppe Foschi 20, Gabriele Missale 21, Alberto Masotto 22, Gerardo Nardone 23, Giovanni Raimondo 24, Francesco Azzaroli 25, Gianpaolo Vidili 26, Filippo Oliveri 27, Filippo Pelizzaro 1, Rafael Ramirez Morales 1, Umberto Cillo 1, Franco Trevisani 28, Luca Miele 29 30, Giulio Marchesini 31, Fabio Farinati 1; Italian Liver Cancer (ITA.LI.CA) group
|
|
|
|
|
Author information
Collaborators
- Italian Liver Cancer (ITA.LI.CA) group:
Anna Sartori, Angela Imondi, Barbara Penzo, Maurizio Biselli, Paolo Caraceni, Francesca Garuti, Annagiulia Gramenzi, Andrea Neri, Davide Ramboldi, Valentina Santi, Alessandro Granito, Luca Muratori, Fabio Piscaglia, Vito Sansone, Francesco Tovoli, Elton Dajti, Giovanni Marasco, Federico Ravaioli, Alberta Cappelli, Rita Golfieri, Cristina Mosconi, Matteo Renzulli, Ester Marina Cela, Antonio Facciorusso, Valentina Cacciato, Edoardo Casagrande, Alessandro Moscatelli, Gaia Pellegatta, Nicoletta de Matthaeis, Gloria Allegrini, Valentina Lauria, Giorgia Ghittoni, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Elisabetta Biasini, Andrea Olivani, Alessandro Inno, Fabiana Marchetti, Anita Busacca, Giuseppe Cabibbo, Calogero Cammà, Vincenzo Di Martino, Giacomo Emanuele Maria Rizzo, Maria Stella Franzè, Carlo Saitta, Assunta Sauchella, Vittoria Bevilacqua, Dante Berardinelli, Alberto Borghi, Andrea Casadei Gardini, Fabio Conti, Alessandro Cucchetti, Anna Chiara Dall'Aglio, Giorgio Ercolani, Claudia Campani, Chiara Di Bonaventura, Stefano Gitto, Pietro Coccoli Antonio Malerba, Mario Capasso, Maria Guarino, Filippo Oliveri, Veronica Romagnoli, Alessandro Di Bucchianico
Affiliations
- 1Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, Italy.
- 2Liver Disease and Transplant Unit, Polytechnic University of Marche, Ancona, Italy gsvegliati@gmail.com.
- 3Obesity Center, Polytechnic University of Marche, Ancona, Italy.
- 4Department of Gastroenterology, Azienda Ospedaliera Marche Nord Pesaro, Pesaro, Italy.
- 5Liver Disease and Transplant Unit, Polytechnic University of Marche, Ancona, Italy.
- 6Department of Gastroenterology, Polytechnic University of Marche, Ancona, Italy.
- 7School of Mathematics and Statistics University of Canterbury, Statistics University of Canterbury, Canterbury, New Zealand.
- 8Department of Internal Medicine, Gastroenterology Unit, University of Genova, IRCCS Policlinico San Martino, Genoa, Italy.
- 9Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- 10Gastroenterology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
- 11Medicine Unit, Azienda Ospedaliera Bolognini, Seriate, Italy.
- 12Gastroenterology Unit, Ospedale Belcolle, Viterbo, Italy.
- 13Department of Medical and Surgical Sciences, Internal Medicine-Zoli Unit, Alma Mater Studiorum - Università di Bologna, Padova, Italy.
- 14Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Puglia, Italy.
- 15Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
- 16Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy.
- 17Gastroenterology Unit, Ospedale Generale Regionale di Bolzano, Bolzano, Italy.
- 18Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples Federico II, Portici, Italy.
- 19Internal Medicine, Gastroenterology, and Liver Unit, University Hospital Agostino Gemelli, Roma, Lazio, Italy.
- 20Department of Internal Medicine, Ospedale degli Infermi di Faenza, Faenza, Emilia Romagna, Italy.
- 21Infectious Diseases and Hepatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Emilia-Romagna, Italy.
- 22Gastroenterology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Veneto, Italy.
- 23Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, Federico II University Hospital, Napoli, Italy.
- 24Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy.
- 25Division of Gastroenterology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- 26Department of Clinical and Experimental Medicine, Universita degli Studi di Sassari, Sassari, Italy.
- 27Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory and Internal Medicine, University of Pisa, Pisa, Italy.
- 28Division of Medical Semeiotics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- 29Internal Medicine and Gastroenterology, Fondazione Policlinico Gemelli, Rome, Italy.
- 30Internal Medicine, Universita Cattolica del Sacro Cuore, Roma, Italy.
- 31Department of Medical & Surgical Sciences, University of Bologna Hospital of Bologna Sant'Orsola-Malpighi Polyclinic, Bologna, Italy.
#Contributed equally.
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new inclusive definition of the whole spectrum of liver diseases associated to metabolic disorders. The main objective of this study was to compare patients with MAFLD and non-MAFLD with hepatocellular carcinoma (HCC) included in a nationally representative cohort.
Methods: We analysed 6882 consecutive patients with HCC enrolled from 2002 to 2019 by 23 Italian Liver Cancer centres to compare epidemiological and future trends in three subgroups: pure, single aetiology MAFLD (S-MAFLD); mixed aetiology MAFLD (metabolic and others, M-MAFLD); and non-MAFLD HCC.
Results: MAFLD was diagnosed in the majority of patients with HCC (68.4%). The proportion of both total MAFLD and S-MAFLD HCC significantly increased over time (from 50.4% and 3.6% in 2002-2003, to 77.3% and 28.9% in 2018-2019, respectively, p<0.001). In Italy S-MAFLD HCC is expected to overcome M-MAFLD HCC in about 6 years. Patients with S-MAFLD HCC were older, more frequently men and less frequently cirrhotic with clinically relevant portal hypertension and a surveillance-related diagnosis. They had more frequently large tumours and extrahepatic metastases. After weighting, and compared with patients with non-MAFLD, S-MAFLD and M-MAFLD HCC showed a significantly lower overall (p=0.026, p=0.004) and HCC-related (p<0.001, for both) risk of death. Patients with S-MAFLD HCC showed a significantly higher risk of non-HCC-related death (p=0.006).
Conclusions: The prevalence of MAFLD HCC in Italy is rapidly increasing to cover the majority of patients with HCC. Despite a less favourable cancer stage at diagnosis, patients with MAFLD HCC have a lower risk of HCC-related death, suggesting reduced cancer aggressiveness.
|
|
|
|
|
|
|
|
|
|
|
|
|